Palisade Bio, Inc. (NASDAQ:PALI) Given Consensus Rating of "Buy" by Brokerages

Shares of Palisade Bio, Inc. (NASDAQ:PALI - Get Free Report) have received an average recommendation of "Buy" from the ten ratings firms that are presently covering the company, Marketbeat reports. One analyst has rated the stock with a sell recommendation, seven have given a buy recommendation and two have assigned a strong buy recommendation to the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $9.00.

A number of analysts recently issued reports on the company. HC Wainwright reissued a "buy" rating and issued a $2.00 target price on shares of Palisade Bio in a research report on Tuesday, June 30th. Wall Street Zen raised Palisade Bio from a "sell" rating to a "hold" rating in a research report on Saturday, July 25th. Oppenheimer started coverage on Palisade Bio in a report on Thursday, July 23rd. They issued an "outperform" rating and a $8.00 price objective for the company. Weiss Ratings lowered shares of Palisade Bio from a "sell (d-)" rating to a "sell (e+)" rating in a research report on Tuesday, July 14th. Finally, LADENBURG THALM/SH SH raised shares of Palisade Bio to a "strong-buy" rating in a report on Thursday, June 25th.

Insiders Place Their Bets

In other Palisade Bio news, CEO John Finley sold 146,798 shares of the firm's stock in a transaction on Tuesday, July 7th. The shares were sold at an average price of $2.07, for a total transaction of $303,871.86. Following the transaction, the chief executive officer directly owned 217,555 shares of the company's stock, valued at approximately $450,338.85. This trade represents a 40.29% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Mitchell Jones sold 51,880 shares of Palisade Bio stock in a transaction on Tuesday, July 7th. The shares were sold at an average price of $2.05, for a total transaction of $106,354.00. Following the completion of the transaction, the insider owned 94,009 shares in the company, valued at approximately $192,718.45. This represents a 35.56% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last three months, insiders have acquired 125,000 shares of company stock valued at $250,100. Insiders own 0.07% of the company's stock.

Hedge Funds Weigh In On Palisade Bio

Several institutional investors have recently added to or reduced their stakes in the stock. Cetera Investment Advisers acquired a new stake in Palisade Bio during the 4th quarter worth approximately $25,000. Schonfeld Strategic Advisors LLC acquired a new position in shares of Palisade Bio in the fourth quarter valued at approximately $26,000. Virtu Financial LLC purchased a new stake in shares of Palisade Bio during the fourth quarter worth approximately $28,000. Legal & General Group Plc purchased a new stake in shares of Palisade Bio during the second quarter worth approximately $30,000. Finally, CTC Alternative Strategies Ltd. purchased a new stake in shares of Palisade Bio during the first quarter worth approximately $31,000. Institutional investors and hedge funds own 11.79% of the company's stock.

Palisade Bio Price Performance

Shares of PALI opened at $2.09 on Tuesday. Palisade Bio has a 1-year low of $0.53 and a 1-year high of $2.86. The stock has a market cap of $364.22 million, a PE ratio of -4.35 and a beta of 1.53. The firm has a fifty day moving average price of $2.03 and a 200 day moving average price of $1.96.

Palisade Bio (NASDAQ:PALI - Get Free Report) last issued its quarterly earnings data on Monday, August 10th. The company reported ($0.05) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.05). The firm had revenue of $0.50 million for the quarter, compared to analysts' expectations of $0.50 million. As a group, equities analysts expect that Palisade Bio will post -0.23 EPS for the current fiscal year.

Palisade Bio Company Profile

Palisade Bio, Inc is a clinical‐stage biotechnology company focused on pioneering localized immunotherapies for the treatment of cancer and inflammatory diseases. The company leverages a proprietary prodrug platform designed to activate therapeutic agents selectively within the tumor microenvironment or sites of inflammation. Its core strategy centers on stimulating the innate immune system via toll‐like receptor 9 (TLR9) agonism to drive targeted immune responses while minimizing systemic exposure and toxicity.

The company’s lead product candidate, PDS0108, is an intratumoral TLR9 agonist prodrug currently in Phase 1/2 clinical trials for patients with advanced solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.